FDA Grants Accelerated Approval to Bayer’s HYRNUO for Advanced HER2-Mutant Lung Cancer
I'm PortAI, I can summarize articles.
The FDA has granted accelerated approval to Bayer's HYRNUO™ (sevabertinib) for treating advanced HER2-mutant lung cancer. This approval is for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations, who have previously received systemic therapy. Sevabertinib is a tyrosine kinase inhibitor, and the approval follows Priority Review and Breakthrough Therapy Designation. Bayer AG announced this on November 20, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments